{"transactions":[{"id":4149399,"issuer":{"id":7637,"kind":"organization","name":"CERENOME, INC."},"owners":[{"id":171571,"kind":"person","name":"HARRIS JOHN DAVID","position":1,"cik":"0001655866","reported_name":"HARRIS JOHN DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP and GM Cell Therapy"}}],"security":"Warrants (Right to Buy)","published_at":"2017-11-29T22:34:41.000Z","date":"2017-11-28","kind":"other","acquired":true,"shares":1800,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, In. (the \"Company\") to all holders of the Company's common stock on October 27, 2017.  The subscription rights entitled each recipient to purchase units (\"Units\").  Each Unit consists of one share of the Company's Series B Preferred Stock (convertible into 3,000 shares of the Company's common stock) and 1,800 warrants, with each warrant representing the right to purchase one share of the Company's common stock.  The purchase price for each Unit was $1,000."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each warrant entitles the holder to purchase one share of the Company's common stock at an exercise price of $0.3333 per share from the date the Company receives stockholder approval of an amendment to its certificate of incorporation to increase its authorized shares of common stock through May 28, 2020."}],"balance_after":1800,"derivative":{"exercise_price":0.3333,"expiration_date":"2020-05-28","underlying":"Common Stock","underlying_shares":1800},"source":{"system":"sec-edgar","filing":"0001209191-17-062897","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1095981/000120919117062897/doc4.xml","form_type":"4"}},{"id":4149398,"issuer":{"id":7637,"kind":"organization","name":"CERENOME, INC."},"owners":[{"id":171571,"kind":"person","name":"HARRIS JOHN DAVID","position":1,"cik":"0001655866","reported_name":"HARRIS JOHN DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP and GM Cell Therapy"}}],"security":"Series B Preferred Stock","published_at":"2017-11-29T22:34:41.000Z","date":"2017-11-28","kind":"other","acquired":true,"shares":1,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, In. (the \"Company\") to all holders of the Company's common stock on October 27, 2017.  The subscription rights entitled each recipient to purchase units (\"Units\").  Each Unit consists of one share of the Company's Series B Preferred Stock (convertible into 3,000 shares of the Company's common stock) and 1,800 warrants, with each warrant representing the right to purchase one share of the Company's common stock.  The purchase price for each Unit was $1,000."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series B Preferred Stock has no expiration date."}],"balance_after":1,"derivative":{"exercise_price":0.3333,"exercise_date":"2017-11-28","underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001209191-17-062897","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1095981/000120919117062897/doc4.xml","form_type":"4"}},{"id":4149397,"issuer":{"id":7637,"kind":"organization","name":"CERENOME, INC."},"owners":[{"id":171571,"kind":"person","name":"HARRIS JOHN DAVID","position":1,"cik":"0001655866","reported_name":"HARRIS JOHN DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP and GM Cell Therapy"}}],"security":"Subscription Rights (Right to Buy)","published_at":"2017-11-29T22:34:41.000Z","date":"2017-11-28","kind":"other","acquired":false,"shares":1,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, In. (the \"Company\") to all holders of the Company's common stock on October 27, 2017.  The subscription rights entitled each recipient to purchase units (\"Units\").  Each Unit consists of one share of the Company's Series B Preferred Stock (convertible into 3,000 shares of the Company's common stock) and 1,800 warrants, with each warrant representing the right to purchase one share of the Company's common stock.  The purchase price for each Unit was $1,000."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, In. (the \"Company\") to all holders of the Company's common stock on October 27, 2017.  The subscription rights entitled each recipient to purchase units (\"Units\").  Each Unit consists of one share of the Company's Series B Preferred Stock (convertible into 3,000 shares of the Company's common stock) and 1,800 warrants, with each warrant representing the right to purchase one share of the Company's common stock.  The purchase price for each Unit was $1,000."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, In. (the \"Company\") to all holders of the Company's common stock on October 27, 2017.  The subscription rights entitled each recipient to purchase units (\"Units\").  Each Unit consists of one share of the Company's Series B Preferred Stock (convertible into 3,000 shares of the Company's common stock) and 1,800 warrants, with each warrant representing the right to purchase one share of the Company's common stock.  The purchase price for each Unit was $1,000."}],"balance_after":0,"derivative":{"exercise_price":1000,"exercise_date":"2017-11-02","expiration_date":"2017-11-21","underlying":"see footnote"},"source":{"system":"sec-edgar","filing":"0001209191-17-062897","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1095981/000120919117062897/doc4.xml","form_type":"4"}},{"id":4380684,"issuer":{"id":7637,"kind":"organization","name":"CERENOME, INC."},"owners":[{"id":171571,"kind":"person","name":"HARRIS JOHN DAVID","position":1,"cik":"0001655866","reported_name":"HARRIS JOHN DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP and GM Cell Therapy"}}],"security":"Incentive Stock Option (right to buy)","published_at":"2017-03-17T21:07:09.000Z","date":"2017-03-08","kind":"grant","acquired":true,"shares":31100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option shares shall vest and become exercisable over four (4) years in forty-eight consecutive monthly installments."}],"balance_after":31100,"derivative":{"exercise_price":1.55,"expiration_date":"2027-03-08","underlying":"Common Stock","underlying_shares":31100},"source":{"system":"sec-edgar","filing":"0001209191-17-021449","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1095981/000120919117021449/doc4a.xml","form_type":"4/A","original_submission_date":"2017-03-10"}},{"id":4391153,"issuer":{"id":7637,"kind":"organization","name":"CERENOME, INC."},"owners":[{"id":171571,"kind":"person","name":"HARRIS JOHN DAVID","position":1,"cik":"0001655866","reported_name":"HARRIS JOHN DAVID","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP and GM Cell Therapy"}}],"security":"Incentive Stock Option (right to buy)","published_at":"2017-03-10T22:56:12.000Z","date":"2017-03-08","kind":"grant","acquired":true,"shares":42000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option shares shall vest and become exercisable over four (4) years in forty-eight consecutive monthly installments."}],"balance_after":42000,"derivative":{"exercise_price":1.55,"expiration_date":"2027-03-08","underlying":"Common Stock","underlying_shares":42000},"source":{"system":"sec-edgar","filing":"0001209191-17-019941","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1095981/000120919117019941/doc4.xml","form_type":"4"}}]}